DrugPatentWatch Database Preview

Details for Patent: 7,091,208

Which drugs does patent 7,091,208 protect, and when does it expire?

Patent 7,091,208 protects XELJANZ XR and XELJANZ and is included in two NDAs.

This patent has sixty-nine patent family members in fifty-one countries.

Summary for Patent: 7,091,208

Title:	Pyrrolo[2,3-D]pyrimidine compounds
Abstract:	A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	11/211,217
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,091,208
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,091,208

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Pfizer Inc	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF RHEUMATOID ARTHRITIS	➤ Sign Up
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TREATMENT OF RHEUMATOID ARTHRITIS	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,091,208

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,601,727	Pyrrolo[2,3-d]pyrimidine compounds	➤ Sign Up
RE41783	Pyrrolo[2,3-D]pyrimidine compounds	➤ Sign Up
6,627,754	Pyrrolo[2,3-d]pyrimidine compounds	➤ Sign Up
7,842,699	Pyrrolo[2,3-D]pyrimidine compounds	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,091,208

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1905	➤ Sign Up
Argentina	026534	➤ Sign Up
Austria	257157	➤ Sign Up
Austria	380031	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,091,208

For more information try a trial or see the plans and pricing